Related Experiment Video

Updated: Apr 21, 2026

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart
08:49

Use of Two Intracorporeal Ventricular Assist Devices As a Total Artificial Heart

Published on: May 11, 2018

8.9K

Ventricular assist device use in congenital heart disease with a comparison to heart transplant

Jacob R Miller1, Pirooz Eghtesady

  • 1Section of Pediatric Cardiothoracic Surgery, Washington University School of Medicine, St Louis Children's Hospital, St Louis, MO 63110, USA.

Journal of Comparative Effectiveness Research
|October 29, 2014
PubMed

Insights

Pediatric ventricular assist devices (VADs) offer a viable treatment for children with congenital heart disease (CHD) and heart failure when transplantation is not possible. This review examines VADs as a bridge to transplant in this unique patient population.

Area of Science:

  • Pediatric cardiology
  • Congenital heart disease (CHD)
  • Mechanical circulatory support

Background:

  • Congenital heart disease (CHD) can lead to progressive heart failure in children, even with advanced treatments.
  • Heart transplantation is the standard treatment, but donor organ limitations pose a significant challenge.
  • End-stage heart failure in pediatric CHD patients presents unique clinical difficulties.

Purpose of the Study:

  • To review the use of pediatric ventricular assist devices (VADs) in children with congenital heart disease (CHD).
  • To evaluate VADs as a bridge-to-transplant therapy in this specific patient group.
  • To compare VAD therapy with heart transplantation for pediatric CHD patients where applicable.

Main Methods:

  • Review of existing literature and clinical experience with pediatric ventricular assist devices (VADs).
  • Analysis of VAD application in patients with congenital heart disease (CHD).
  • Comparative assessment of VAD therapy versus heart transplantation outcomes.

Main Results:

  • Pediatric ventricular assist devices (VADs) are emerging as a crucial treatment option for children with congenital heart disease (CHD) and heart failure.
  • VADs serve as a viable bridge-to-transplant therapy, addressing donor limitations.
  • Limited data exists on pediatric VADs specifically within the CHD population due to case rarity and complexity.

Conclusions:

  • Pediatric ventricular assist devices (VADs) represent a significant advancement for managing heart failure in children with congenital heart disease (CHD).
  • VADs provide a critical alternative when heart transplantation is not immediately feasible.
  • Further research is needed to fully understand the long-term efficacy and application of VADs in pediatric CHD patients.

Keywords:
congenital heart diseaseheart failureheart transplantpediatricsingle ventricleventricular assist device

More Related Videos

Implantation of Total Artificial Heart in Congenital Heart Disease07:27

Implantation of Total Artificial Heart in Congenital Heart Disease

Published on: July 18, 2014

28.4K
Implantation of the Syncardia Total Artificial Heart16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

36.8K

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
742
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
766
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
624